These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 10765224)
1. Management of Toxicities of Combined Modality Therapy for Intrathoracic Malignancies. Weakland T; Wagner H Cancer Control; 1996 Jul; 3(4):329-335. PubMed ID: 10765224 [TBL] [Abstract][Full Text] [Related]
2. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer. Mehta V Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522 [TBL] [Abstract][Full Text] [Related]
3. Complications of pelvic radiation in patients treated for gynecologic malignancies. Viswanathan AN; Lee LJ; Eswara JR; Horowitz NS; Konstantinopoulos PA; Mirabeau-Beale KL; Rose BS; von Keudell AG; Wo JY Cancer; 2014 Dec; 120(24):3870-83. PubMed ID: 25056522 [TBL] [Abstract][Full Text] [Related]
4. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy. Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108 [TBL] [Abstract][Full Text] [Related]
5. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer]. Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776 [TBL] [Abstract][Full Text] [Related]
6. Management of the oral sequelae of cancer therapy. Jones DL; Rankin KV Tex Dent J; 2012 May; 129(5):461-8. PubMed ID: 22779202 [TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253 [TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735 [TBL] [Abstract][Full Text] [Related]
9. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. Lee CB; Stinchcombe TE; Moore DT; Morris DE; Hayes DN; Halle J; Rosenman JG; Rivera MP; Socinski MA J Thorac Oncol; 2009 Jan; 4(1):74-9. PubMed ID: 19096310 [TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Robert F; Childs HA; Spencer SA; Redden DT; Hawkins MM Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):136-47. PubMed ID: 10210553 [TBL] [Abstract][Full Text] [Related]
11. Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. Coia LR; Engstrom PF; Paul A J Clin Oncol; 1987 Nov; 5(11):1783-90. PubMed ID: 2445931 [TBL] [Abstract][Full Text] [Related]
12. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group. Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106 [TBL] [Abstract][Full Text] [Related]
13. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237 [TBL] [Abstract][Full Text] [Related]
14. Neurologic, pulmonary, and cutaneous toxicities of high-dose chemotherapy. Armstrong T; Rust D; Kohtz JR Oncol Nurs Forum; 1997; 24(1 Suppl):23-33. PubMed ID: 9010862 [TBL] [Abstract][Full Text] [Related]
15. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Morota M; Gomi K; Kozuka T; Chin K; Matsuura M; Oguchi M; Ito H; Yamashita T Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):122-8. PubMed ID: 19327900 [TBL] [Abstract][Full Text] [Related]
16. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393 [TBL] [Abstract][Full Text] [Related]
17. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Ouwerkerk J; Boers-Doets C Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896 [TBL] [Abstract][Full Text] [Related]
18. An overview of chemotherapy toxicities. Peters BG Top Hosp Pharm Manage; 1994 Jul; 14(2):59-88. PubMed ID: 10136204 [TBL] [Abstract][Full Text] [Related]
19. The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. Monjazeb AM; Blackstock AW Semin Radiat Oncol; 2013 Jan; 23(1):60-73. PubMed ID: 23207048 [TBL] [Abstract][Full Text] [Related]
20. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]